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Myeloperoxidase (MPO) is an enzyme stored in azurophilic granules of polymorphonuclear neutrophils and macrophages and re-
leased into extracellular ﬂuid in the setting of inﬂammatory process. The observation that myeloperoxidase is involved in oxidative
stress and inﬂammation has been a leading factor to study myeloperoxidase as a possible marker of plaque instability and a useful
clinical tool in the evaluation of patients with coronary heart disease. The purpose of this review is to provide an overview of the
pathophysiological, analytical, and clinical characteristics of MPO and to summarize the state of art about the possible clinical use
of MPO as a marker for diagnosis and risk stratiﬁcation of patients with acute coronary syndrome (ACS).
Copyright © 2008 Valentina Loria et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Myeloperoxidase (MPO) is a well-known enzyme, mainly
released by activated neutrophils, characterised by power-
ful pro-oxidative and proinﬂammatory properties. Recently,
myeloperoxidase has been proposed as a useful risk marker
and diagnostic tool in acute coronary syndromes and in pa-
tients admitted to emergency room for chest pain.
2. PATHOPHYSIOLOGICAL ROLE OF
MYELOPEROXIDASE IN ISCHEMIC
HEART DISEASE
Oxidative stress and inﬂammation play important roles in
the pathogenesis of destabilization of coronary artery disease
(CAD)leadingtoacutecoronarysyndromes(ACS).Inﬁltrat-
ing macrophages and neutrophils participate in the trans-
formation of stable coronary artery plaques to unstable le-
sions [1, 2]. Recently, there has been a renewed interest in
MPO, a proinﬂammatory enzyme that is abundant in rup-
tured plaque [3]a n dc a nb em e a s u r e di np e r i p h e r a lb l o o d .
MPO is a hemoprotein that is stored in azurophilic granules
of polymorphonuclear neutrophils and macrophages. MPO
catalyzes the conversion of chloride and hydrogen peroxide
to hypochlorite and is secreted during inﬂammatory condi-
tion. It has been implicated in the oxidation of lipids con-
tained within LDL cholesterol. In addition, MPO consumes
endothelial-derived NO,therebyreducingNObioavailability
and impairing its vasodilating and anti-inﬂammatory prop-
erties.
Major evidence for MPO as enzymatic catalyst for oxida-
tive modiﬁcation of lipoproteins in the artery wall has been
suggestedinanumberofstudiesperformedwithlow-density
lipoprotein [4]. In contrast to low-density lipoprotein,
plasma levels of high-density lipoprotein (HDL)-cholesterol
and apoAI, the major apolipoprotein of HDL, inversely cor-
relate with the risk of developing coronary artery disease.
There is now strong evidence that HDL is a selective in vivo
target for MPO-catalyzed oxidation, that may represent a
speciﬁc molecular mechanism for converting the cardiopro-
tectivelipoproteinintoadysfunctionalform,raisingthepos-
sibilitythattheenzymerepresentsapotentialtherapeutictar-
get for preventing vascular disease in humans [5]. Zhou et al.
[6] showed that atorvastatin reduced serum MPO and CRP
concentrations in patients with ACS.
MPO activity can be measured in blood and tissues by
spectrophotometric assays using hydrogen peroxide and o-
dianisidine dihydrochloride as substrates. In addition, MPO
content can be measured in neutrophils as an index of de-
granulation with the Coulter counter and ﬂow cytometry
and circulating MPO by ELISA. Very recently, commercial
methods allowing low-cost and high-volume measurements2 Mediators of Inﬂammation
have been proposed. The introduction of these methods of
measurement might make MPO a new and useful cardiac
biomarker.
3. CLINICAL EVIDENCES FOR MPO AS
A CARDIAC BIOMARKER
3.1. Primaryprevention
There have been a few but important clinical studies examin-
ingtheroleofMPOasamarkerofriskforCAD.Usinganen-
zyme assay, Zhang et al. [7] showed that blood and leukocyte
MPO activity were higher in patients with CAD than angio-
graphically veriﬁed normal controls, and that this increased
activity was signiﬁcantly associated with presence of CAD
(odds ratio, 11.9; 95% conﬁdence interval (CI), 5.5–25.5).
Results were independent of the patient’s age, sex, hyperten-
sion, smoking, or diabetes status, LDL concentration, leuko-
cytecount,andFraminghamglobalriskscore.Morerecently,
Meuwese et al. [8], in the EPIC- (European prospective in-
vestigation into cancer and nutrition-) Norfolk prospective
populationstudy,haveevaluatedtheassociationofMPOlev-
els with the risk of future CAD in apparently healthy indi-
viduals. MPO was measured in baseline samples of a case-
control study nested in the prospective EPIC-Norfolk popu-
lationstudy:casesubjects(n =1138)wereapparentlyhealthy
men and women who developed CAD during 8 years of
follow-up; control subjects (n = 2237) matched for age, gen-
der, and enrollment time, remained free of CAD. The MPO
levels were signiﬁcantly higher in case subjects than in con-
trol subjects and correlated with C-reactive protein (CRP)
and white blood cell count. Risk of future CAD increased in
consecutive quartiles of MPO concentration, with an odds
ratio(OR)of1.49inthetopversusbottomquartile.Afterad-
justment for traditional risk factors, the OR in the top quar-
tile remained signiﬁcant at 1.36 (95% CI 1.07 to 1.73). Of
interest in this study, serum MPO levels were associated with
the risk of future development of CAD in apparently healthy
individuals,buttheassociationwasweakerthanthatoftradi-
tional risk factors and CRP. However MPO, at variance from
CRP, was largely independent from classical risk factors.
3.2. Secondaryprevention
In ACS, MPO has been consistently found to be associated
withthepresenceofinstabilityandriskoffutureeventsinthe
studies that have explored these topics. Biasucci et al. [9]ﬁ r s t
observed that circulating neutrophils in patients with acute
myocardial infarction (AMI) and unstable angina (UA) have
alowMPOcontent,andthereforehighMPOlevelsinthecir-
culation, as compared with those with chronic stable angina
and variant angina. This is indicative of a signiﬁcant release
ofMPOfromneutrophilsrelatedtotheiractivation.Thelack
of neutrophil activation in patients with variant angina, and
after stress test suggests that this phenomenon may occur in-
dependently of ischemic episodes. Therefore, MPO is preva-
lently a marker of instability and not simply a marker of ox-
idative stress and damage. Furthermore, in this study MPO
did not correlate with CK-MB and troponin T release; this
observation is clinically important as an extremely sensitive
and speciﬁc marker of damage already exists (troponin), but
no deﬁnite markers of instability exists so far. In this study,
MPO content was determined on the Coulter counter, which
measures the neutrophil count by ﬂow cytometry and subse-
quentlycalculatesthemeanMPOcontentinthatpopulation.
Using the same method, Buﬀon et al. [10] studied 65 pa-
tients who underwent cardiac catheterization with coronary
sinussampling.TheMPOcontentoftheleukocytescollected
from the arterial circulation and the coronary sinus eﬄuent
werecompared.TheauthorsfoundagradientofMPOacross
the coronary circulation in patients with ACS and this gradi-
ent was present even when the culprit lesion involved with
the ACS was in the distribution of the right coronary artery,
which does not drain into the coronary sinus. In this study,
as in the previous one, a signiﬁcant correlation was found
between systemic levels of C-reactive protein and either the
aortic and coronary sinus neutrophil MPO.
The potential usefulness for risk stratiﬁcation of blood
concentrations of MPO was examined in 2 recent studies.
In the CAPTURE trial [11], MPO mass concentration was
measured in 1090 patients with ACS. Rates of death and
myocardial infarction (MI) were determined at 6months of
follow-up. An MPO cutoﬀ of 350µg/L was associated with
an adjusted hazard ratio was 2.25 (95% CI, 1.32–3.82). The
eﬀects were particularly impressive in patients with unde-
tectable cardiac troponin T (cTnT < 0.01µg/L), in whom the
hazard ratio was 7.48 (95% CI, 1.98–28.29). Of interest, the
increase in risk was already evident after 72 hours, increas-
ing only slightly thereafter (Figure 1). This observation is in
keepingwiththedatabyBiasuccietal.[9]whohadshownre-
turn of MPO to baseline levels in all patients, including those
with myocardial infarction, within one week. This point is
important, as suggests a peculiar characteristic of MPO, at
variance from other inﬂammatory markers commonly used
(as CRP, ﬁbrinogen) and from other proposed inﬂammatory
markers that remain elevated for relatively long time or have
an extremely short and unreliable half-life (such as inter-
leukins). The predictive value of MPO was independent by
C-reactive protein and high MPO serum levels indicated in-
creased cardiac risk both in patients with medium C-reactive
protein serum levels (20.0% versus 5.9%; P < .001) and in
those with low C-reactive protein serum levels (17.8% versus
0%;P<.001),suggestingthatrecruitmentanddegranulation
of neutrophils is a primary event and is followed by release
of other systemic mediators and acute-phase proteins such
as C-reactive protein. At variance from CRP levels, levels of
MPOwerenotinﬂuencedbytroponin,suggestingaprognos-
tic role of MPO independent from troponin and conﬁrming
that inﬂammation is a primary phenomenon in ACS.
In a study of 604 consecutive patients presenting to the
emergency department with chest pain, Brennan et al. [12]
demonstrated a progressive increase in odds ratios for ma-
jor adverse events at 30 days and 6 months with each quar-
tile increase in MPO concentration in patients with negative
troponin. The 6-month outcomes were similar to the results
of the CAPTURE trial: corresponding odds ratios were 1.6
(95% CI, 1.0–2.7), 3.6 (2.2–5.8), and 4.7 (2.9–7.7) for the
second, third, and fourth quartiles, respectively (cut oﬀso fValentina Loria et al. 3
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Figure 1: Increase in risk of death (D) plus MI (myocardial infarc-
tion) with increasing tertiles of MPO [11].
119, 198, and 394pmol/L, resp.). It is of interest that, even
in the absence of myocardial necrosis and in negative car-
diac troponin patients, baseline measurements of MPO sig-
niﬁcantly enhanced the identiﬁcation of patients at risk, al-
though this study included the “need for revascularization”
within the deﬁnition of major adverse cardiac events and
used an inappropriately high cTnT cutoﬀ of 0.10µg/L. Fur-
thermore, while troponin T takes three to six hours to rise to
measurable circulating levels after myocardial injury, MPO
levels were signiﬁcantly elevated at baseline (even within two
hours after the onset of symptoms) in patients who were ini-
tially negative for troponin T. These ﬁndings suggest that
measurement of MPO levels may be useful in triage in the
emergency department and that elevated plasma MPO lev-
els may be a marker of unstable angina preceding myocardial
necrosis and therefore, a predictor of vulnerable plaque. In-
terestingly, C-reactive protein levels predicted the risk of my-
ocardial infarction at presentation for the entire cohort but
were not predictive of major adverse cardiac events in the
group that was negative for troponin T. In the cohort that
was consistently negative for troponin T, the areas under the
curve for MPO were signiﬁcantly higher than those for tro-
ponin T, CK-MB, and C-reactive protein.
Taken together, these data suggest that CRP and MPO
may be complementary and explore diﬀerent ﬁelds: CRP is a
marker of disease activity and vascular inﬂammation, and is
usefulforlong-termriskstratiﬁcationwhileMPOisamarker
of plaque instability and neutrophil activation and may be
associated with short-term stratiﬁcation, in particular in pa-
tients with troponin negative levels.
More recently, several studies have also investigated the
value of MPO in predicting long-term outcomes. Recently,
S.-H. Li et al. [13] have studied 176 consecutive patients who
underwent coronary angiography. The patients were divided
intofourgroupsaccordingtothequartileofMPOlevel.They
have found that: (1) ACS rate (36.2%) in the fourth quartile
group of MPO level was 6 times higher than that in the ﬁrst
quartile group of MPO level, P < .01. (2) Gensini score in the
fourth quartile group of MPO level was signiﬁcantly higher
than that in the ﬁrst quartile group (P < .01). WBC in the
fourth quartile group was also signiﬁcantly higher than that
in the ﬁrst quartile group, P < .05. In addition, Kaplan-Meier
Table 1: Prognostic and diagnostic value and analytical perfor-
mance of inﬂammatory markers in CAD: myeloperoxidase (MPO),
C reactive protein (CRP), pregnancy-associated plasma protein-A
(PAPP-A), CD40 ligand (CD40L), and interleukins.
Inﬂammatory markers in CAD
Prognosis Diagnosis Analyt. perform.
MPO +++ ++ ++ (more?)
CRP ++++ +/− ++++
PAPP-A ++ + −
CD40L ++ +/−−
Interleukins +++ +/−−
event rate curve showed that there was a signiﬁcant diﬀer-
enceinoutcome(death,AMI,revascularization)betweenthe
groupswithMPO≥ 62.9AUU/Land ≤ 62.9AUU/LofMPO
serum level at 6-month follow-up visit (chi(2) = 13.5, P =
.01).Furthermore,Cavusogluetal.[14]haveinvestigatedthe
long-termprognosticsigniﬁcanceofbaselineMPOlevelsina
well-characterized cohort of 193 men with ACS. All patients
were followed prospectively for the development of death
and MI, and follow-up data were available for all patients at
24 months. Using the median MPO value of the entire co-
hort of patients (20.34ng/mL) as a prespeciﬁed cutoﬀ, the
MI-free survival at 24 months for the group with MPO val-
ues below cutoﬀ were signiﬁcantly lower than in those with
values above cutoﬀ.
Mocatta et al. have investigated the relationship between
plasma MPO and clinical outcome after AMI [15, 16]. They
have studied 512AMI patients at hospital admission and
have measured plasma MPO in AMI patients and found a
signiﬁcant association of MPO with follow-up events. Im-
portantly, MPO was of incremental prognostic value on the
top of ejection fraction and BNP, a ﬁnding observed also by
Khan in a similar population of patients with STEMI [17].
4. CONCLUSIONS
MPO is a marker of inﬂammation and oxidative stress that
has been consistently demonstrated to be elevated in pa-
tients with ACS. However, the data so far available are rel-
atively few; therefore, more studies are requested to precisely
deﬁne the role of MPO. In particular all studies involving
MPO assessment have used diﬀerent methods, thus a stan-
dardization eﬀort is needed. Furthermore, increased MPO
is not likely to be speciﬁc for cardiac diseases, as activation
of neutrophils and macrophages can occur in any infectious,
inﬂammatory, or inﬁltrative process, therefore, more studies
should address and clarify these points. So far, as reported in
Table 1,MPOseemstohave,amongtheinﬂammatorymark-
ers, a role superior to that of pregnancy-associated plasma
protein-A (PAPP-A), CD40 ligand (CD40L), and cytokines,
but still inferior to CRP.
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